Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$261.99
▲ $0.09 (+0.0%)
Market data updated: 09/19 02:41 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$21.10B
Day Range
$258.55 - $265.83
52-Week Range
$157.58 - $283.05
Beta
—
Next Earnings
26.10.2026
Support
$179.91
Resistance
$283.05
THC is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+37.7% (1Y)
Strengths: 10/27 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟡 Mixed
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
DCF Fair Value
Estimated fair value: $450.63 vs. price $261.99 (+72.0%)
Fair Value
Biggest negative driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: -52.6%
Growth
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
62
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 26, 2026
Then
69
$271.88
Now
62
$261.99
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
48
Quality
58
Value
62
Momentum
53
Risk
56
Sentiment
100
Fundamental
66
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Tenet Healthcare Corporation has centered on two major financial transactions: the company’s upsized $2 billion private offering of senior notes (due 2034) to refinance existing debt, and the sale of a $1.6 billion stake in Tenet by Cerberus Capital to CBRE Investment Management. Additionally, Tenet Fintech Group (a separate entity) announced sponsorship of the Ignite 2026 accounting conference, though unrelated to Tenet Healthcare’s core operations. The focus remains on debt restructuring and ownership shifts.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Tenet Healthcare Corporation. News trend score: 100. Reason: 15 of the last 20 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
27
🎯 Conviction (vs. Emotion)
40
Psychology
31
Fundamentals
66
Technical
53
Valuation
62
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+52%
Market Narrative
50
Fundamental Reality
40
Narrative Gap
+10
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests **herding** dominates, as THC’s decline (-2.3%) mirrors its peers (-4.9%), reducing relative risk perception. Elevated volume (1.10x) and positive sentiment (80/100) hint at speculative interest, but neutral RSI (47) and negative momentum (-5.0% ROC) temper euphoria. The narrative gap (-2) implies minor misalignment, but the key question remains: *Will peer performance sustain THC’s alignment, or will divergence emerge?*
Updated: 09/09/2026, 09:23 AM
What could change this?
👥 What the crowd believes
"$2.0 billion in aggregate principal amount of senior notes due 2034"
"private placement offering of $1.5 billion in new senior notes to refinance $1.5 billion in outstanding notes"
"Cerberus sold Tenet Equity to CBRE for $1.6 billion"
"THC added to Zacks Rank #1 (Strong Buy) List"
📈 13D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 67/100
🔴 Weakest match
Peter Lynch — 24/100
🗣️ Why do they disagree?
Based on the documented principles of each methodology, the higher‑scoring investors like Nelson (67) and Housel (60) view the stock as favorably positioned in its cycle and reasonably holdable, while mid‑range scores from Fisher, Mackay, and Bagehot (57‑56) acknowledge solid fundamentals but stop short of calling it exceptional, noting crowd enthusiasm and adequate liquidity. Value‑oriented lenses such as Graham (54) and Marks (53) produce mixed verdicts, reflecting uncertainty about margin of safety and potentially elevated expectations. More conservative or risk‑averse frameworks, including Livermore (43), Veblen (36), and Smith (35), flag negative trends, growth pursued for its own sake, or insufficient stability, leading to outright avoidance. The divergence stems from each investor’s emphasis—cycle timing, intrinsic quality, margin of safety, or growth sustainability—resulting in a spectrum of opinions from cautiously optimistic to decidedly negative.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 67
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 60
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 57
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 57
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 56
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 54
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 53
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 52
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 51
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 44
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 43
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 37
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 36
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 35
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 29
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 24
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟡 Indicators are mixed — no clear bias (4 bullish · 5 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
16.5%
Net Margin
11.1%
EBITDA Margin
20.5%
ROE
56.1%
ROA
8.0%
ROIC
—
EPS
$15.61
Cash
$2.88B
Total Debt
—
Current Ratio
1.76
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$261.99
Estimated Fair Value (DCF)
$450.63
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+72.0%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
3.6%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 3.6% | $2.62B | $2.41B |
| 2 | 3.3% | $2.71B | $2.28B |
| 3 | 3.1% | $2.79B | $2.16B |
| 4 | 2.8% | $2.87B | $2.03B |
| 5 | 2.5% | $2.94B | $1.91B |
Base FCF (last actual year)
$2.53B
Terminal Value
$46.38B
Present Value of Terminal Value
$30.15B
Enterprise Value
$40.93B
Net Debt
$0
Equity Value
$40.93B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$46.46
Tangible Book Value per Share (Tangible NAV)
-$91.66
Sentiment based on basic keywords (not AI) — 15 positive, 2 neutral, 3 negative out of the last 20 articles.
Yahoo · 18.9.2026
ChartMill · 18.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Benzinga · 14.9.2026
Yahoo · 14.9.2026
Yahoo · 14.9.2026
Yahoo · 14.9.2026
CRE Daily · 11.9.2026
Yahoo · 11.9.2026
Tenet Healthcare Corporation (THC) currently has a StockIQ AI score of 62/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
THC currently scores 62/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, THC's estimated fair value is $450.63, which is 72.0% above the current price of $261.99. This is one valuation model among several signals in the fair-value category, not a price target.
THC's technical score is 53/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Estimated fair value: $450.63 vs. price $261.99 (+72.0%); Free cash flow growth: 126.7%; Operating margin is stable or improving over time.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: -52.6%; Net income growth: -41.8%; MACD histogram is negative — falling momentum.
StockIQ has no recorded dividend payment history for THC.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 23 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| West Nadja | Open Market Sale | 2.9.2026 | 1,152 | -1,152 | $258.80 |
| Foo Lisa Y | Open Market Sale | 31.8.2026 | 24,000 | -24,000 | $266.32 |
| HANEY CECIL D | Gift | 28.8.2026 | 12,403 | -150 | — |
| HANEY CECIL D | Gift | 28.8.2026 | 150 | -150 | — |
| Sutaria Saumya | Open Market Sale | 25.8.2026 | 441,463 | -24,881 | $274.10 |
| Sutaria Saumya | Open Market Sale | 25.8.2026 | 466,344 | -17,220 | $273.34 |
| Sutaria Saumya | Open Market Sale | 25.8.2026 | 433,564 | -7,899 | $275.26 |
| Sutaria Saumya | Open Market Sale | 25.8.2026 | 17,220 | -17,220 | $273.34 |
| Sutaria Saumya | Open Market Sale | 25.8.2026 | 24,881 | -24,881 | $274.10 |
| Sutaria Saumya | Open Market Sale | 25.8.2026 | 7,899 | -7,899 | $275.26 |
| Sutaria Saumya | Open Market Sale | 24.8.2026 | 483,564 | -36,656 | $278.90 |
| Sutaria Saumya | Open Market Sale | 24.8.2026 | 520,220 | -13,344 | $278.17 |
| HANEY CECIL D | Open Market Sale | 24.8.2026 | 12,553 | -1,300 | $278.03 |
| Sutaria Saumya | Open Market Sale | 24.8.2026 | 13,344 | -13,344 | $278.17 |
| HANEY CECIL D | Open Market Sale | 24.8.2026 | 1,300 | -1,300 | $278.03 |
| Sutaria Saumya | Open Market Sale | 24.8.2026 | 36,656 | -36,656 | $278.90 |
| Romo Tammy | Open Market Sale | 7.8.2026 | 2,500 | -2,500 | $260.83 |
| Romo Tammy | Open Market Sale | 7.8.2026 | 28,284 | -2,500 | $260.83 |
| Romo Tammy | Open Market Sale | 6.8.2026 | 4,922 | -4,922 | $264.15 |
| Romo Tammy | Open Market Sale | 6.8.2026 | 30,784 | -4,922 | $264.15 |
| Blunt Roy | Open Market Sale | 5.8.2026 | 600 | -600 | $262.68 |
| Blunt Roy | Open Market Sale | 5.8.2026 | 4,589 | -600 | $262.68 |
| Foo Lisa Y | Open Market Sale | 29.7.2026 | 10,000 | -10,000 | $258.03 |
| Foo Lisa Y | Open Market Sale | 29.7.2026 | 32,053 | -10,000 | $258.03 |
| BIERMAN JAMES L | Open Market Sale | 27.7.2026 | 5,000 | -5,000 | $244.96 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
1,887,387 shares short as of 2026-08-31 · vs. 3,200,670 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
60.7% of trading volume this week was short selling, vs. 58.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology